Tirzepatide vs. Cagrilintide/Semaglutide: A New Frontier in Pharmacological Management of Obesity
DOI:
https://doi.org/10.12775/JEHS.2026.95.73651Keywords
tirzepatide, cagrilintide, semaglutide, CagriSema, obesity pharmacotherapy, GLP-1 receptor agonist, GIP receptor agonist, amylin analogue, SURMOUNT, REDEFINE, weight loss, incretin therapy, dual agonist, triple hormone receptorAbstract
Obesity is a chronic, multifactorial disease with escalating global prevalence, associated with profound metabolic, cardiovascular, and oncological comorbidities. The recent emergence of incretin-based and amylin-receptor pharmacotherapies has fundamentally transformed the landscape of obesity treatment. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), and the investigational combination of cagrilintide - a long-acting amylin analogue - with semaglutide (CagriSema) represent two of the most clinically significant advances in weight management pharmacology. Both approaches achieve unprecedented levels of body weight reduction in clinical trials, yet differ substantially in their receptor targets, mechanisms of action, and adverse-effect profiles.
References
1. World Health Organization. Obesity and overweight. Fact sheet. WHO; 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
3. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626.
4. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2970–2978.
5. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48.
6. Jastreboff AM, Kushner RF, Jedd MA, et al. Tirzepatide versus semaglutide 2.4 mg for obesity treatment in adults (SURMOUNT-5): a randomised, double-blind, phase 3b trial. Lancet. 2025;405(10478):503–515.
7. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515.
8. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management in adults with overweight or obesity: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10288):1736–1748.
9. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380.
10. Willard FS, Sloop KW, Emmerson PJ, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
11. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130.
12. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30.
13. Khoo B, Tan TM. Combination gut hormone therapy for obesity: from bench to bedside. Curr Opin Endocrinol Diabetes Obes. 2021;28(5):420–427.
14. Ryan PM, Samsell L, Zhu H, et al. Amylin and GLP-1: complementary satiety hormones with separate and synergistic mechanisms. Regul Pept. 2019;252:1–6.
15. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–551.
16. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
17. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232.
18. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–150.
19. Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43(6):1352–1355.
20. Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30(3):202–210.
21. Gao X, Bhatt DL. Tirzepatide reduces major adverse cardiovascular events: SURMOUNT-MMO trial design. Am Heart J. 2024;267:45–57.
22. Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14–19.
23. Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121(6):21–33.
24. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–1409.
25. Obesity Canada / Canadian Association of Bariatric Physicians and Surgeons. Canadian Adult Obesity Clinical Practice Guidelines, 2023 Update. Obesity Canada; 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Marcelina Rybińska, Hanna Rzepka, Paweł Stępowski, Mateusz Tajster
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 112
Number of citations: 0
